^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CHEK2 mutation

    i
    Other names: CHEK2, bA444G7, CDS1, CHK2, HuCds1, PP1425, RAD53, Checkpoint kinase 2
    Entrez ID:
    11200
    Related biomarkers:
    Mutation
    Related tests:
    11ms
    Response to bipolar androgen therapy and PD-1 inhibition in a patient with metastatic castration-resistant #ProstateCancer and a germline CHEK2 mutation. #BeyondTheAbstract on UroToday > https://t.co/SCpyBX12Gv @MattLabsMD @EAntonarakis @AarmstrongDuke @BMJCaseReports (@urotoday)
    Clinical • IO biomarker • Metastases
    |
    CHEK2 (Checkpoint kinase 2) • YBX1 (Y-Box Binding Protein 1)
    |
    CHEK2 mutation
    12ms
    Response to bipolar androgen therapy and PD-1 inhibition in a patient with metastatic castration-resistant #ProstateCancer and a germline CHEK2 mutation. #BeyondTheAbstract on UroToday > https://t.co/SCpyBX12Gv @MattLabsMD @EAntonarakis @AarmstrongDuke @BMJCaseReports (@urotoday)
    Clinical • IO biomarker • Metastases
    |
    CHEK2 (Checkpoint kinase 2) • YBX1 (Y-Box Binding Protein 1)
    |
    CHEK2 mutation
    1year
    Response to bipolar androgen therapy and PD-1 inhibition in a patient with metastatic castration-resistant #ProstateCancer and a germline CHEK2 mutation. #BeyondTheAbstract on UroToday > https://t.co/SCpyBX12Gv @MattLabsMD @EAntonarakis @AarmstrongDuke @BMJCaseReports (@urotoday)
    Clinical • IO biomarker • Metastases
    |
    CHEK2 (Checkpoint kinase 2) • YBX1 (Y-Box Binding Protein 1)
    |
    CHEK2 mutation
    1year
    SCI members Ester John, @AllisonKurian and others found that patients who carry a germline #BRCA1, #BRCA2 or #CHEK2 mutation have at least a twofold increased risk of developing cancer in both breasts. https://t.co/z5oNU5mGO3 #ContralateralBreastCancer (@SCIDirector)
    Clinical
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • CHEK2 (Checkpoint kinase 2)
    |
    CHEK2 mutation
    1year
    CHMP recommends naraparib/abi for 1st line CRPC with BRCA1/2 mutations only, based on MAGNITUDE, but this had a wider HRR biomarker panel (ATM, BRIP1, CDK12, CHEK2, FANCA, HDAC2, PALB2). Are these just passengers?⬆️ momentum for BRCA for PARPi in CRPC https://t.co/ZjbyXDxo27 (@tompowles1)
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PALB2 (Partner and localizer of BRCA2) • CDK12 (Cyclin dependent kinase 12) • BRCA (Breast cancer early onset) • CHEK2 (Checkpoint kinase 2) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • HDAC2 (Histone deacetylase 2)
    |
    BRCA2 mutation • BRCA1 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • FANCA mutation
    over1year
    .@SidYadavMD presents pop-based study of rates of contralateral breast ca in genetic mutation carriers - 10yr CBC absolute risk was 23% in BRCA1 & 17% in BRCA2. ⬆️ also for CHEK2. Unknown endocrine tx use. Important data when discussing contralateral RRM w/ pts #SABCS22 (@puneetsinghmd)
    Clinical • Absolute risk
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • CHEK2 (Checkpoint kinase 2)
    |
    BRCA1 mutation • CHEK2 mutation
    over1year
    Germline mutations in CHEK2, ATM, and BRCA2 are associated with #bladdercancer risk in newly published data from #UKBiobank @JianfengXuDrPH @prost8helf @Jtkearns @apglaser https://t.co/SpDWizVrfx (@NorthShoreUro)
    BRCA2 (Breast cancer 2, early onset) • CHEK2 (Checkpoint kinase 2)
    |
    ATM mutation • CHEK2 mutation
    over1year
    Interesting data from Cezary Cybulski showing that CHEK2 mutations increase the risks for several cancers (breast, prostate, thyroid) but somehow decrease the risk for lung cancer. #CGAIGC22 @CKoptiuch (@HHampel1)
    CHEK2 (Checkpoint kinase 2)
    |
    CHEK2 mutation
    2years
    For women w germline pathogenic ATM, CHEK2, PALB2, mutations, comparative modeling suggests that "screening MRI starting at age 30 to 35 years may substantially reduce breast cancer mortality..." #bcsm @OncoAlert @JAMAOnc @MarkRobsonMD @AllisonKurian https://t.co/FlJexj8r6u (@StoverLab)
    PALB2 (Partner and localizer of BRCA2) • CHEK2 (Checkpoint kinase 2)
    |
    PALB2 mutation • CHEK2 mutation
    2years
    For Less Familiar Gene Mutations #ATM, #CHEK2, and #PALB2 linked to #breastcancer: Research Aims to Create Screening Guidelines with @MarkRobsonMD @sloan_kettering #bcsm #hereditarycancer #cancerresearch #genetics #womenshealth https://t.co/9bx7vVndxy (@LguzzardiM)
    ATM (ATM serine/threonine kinase) • PALB2 (Partner and localizer of BRCA2) • CHEK2 (Checkpoint kinase 2)
    |
    ATM mutation • PALB2 mutation • CHEK2 mutation
    over2years
    23% of all #patients w/ #testicularcancer #germlinetesting had pathogenic mutations, 19% in DNA-damage repair genes (e.g. ATM, CHEK2). #DrChethanRamamurthy @UTHealthSA @sonpavde @DanaFarber @Invitae @UrolOncol #access #genetictesting #clinicaltrials https://t.co/NtQY1QabY9 (@EdEsplin)
    Clinical
    |
    ATM (ATM serine/threonine kinase) • CHEK2 (Checkpoint kinase 2)
    |
    ATM mutation • CHEK2 mutation
    over2years
    A case of metastatic pancreatic cancer with germline CHEK2 mutation who achieved a complete response after platinum-based chemotherapy @letswinpc @PanCAN @PancreaticCanUK @CathyEngMD @Latinamd @GIOncologist https://t.co/48Nmp3xgQX (@MaenAbdelrahim)
    Clinical
    |
    CHEK2 (Checkpoint kinase 2)
    |
    CHEK2 mutation
    3years
    Figure from this week's @NEJM tells you all you need to know about lifetime risk of breast cancer based on hereditary gene mutations. BRCA1/2 & PALB2 highly penetrant; CHEK2, BARD1, ATM much less so. Important for prophylaxis and surveillance plans. (@DrHBurstein)
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PALB2 (Partner and localizer of BRCA2) • CHEK2 (Checkpoint kinase 2) • BARD1 (BRCA1 Associated RING Domain 1)
    |
    BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • CHEK2 mutation • BARD1 mutation
    over3years
    And finally a couple genetic risk studies to take a close look at: #10 - ✅Abs. 44 Dr. Ozair - Characteristics of pts with a GI cancer personal or FH and CHEK2 mutations #11 - ✅Abs. 45 Dr. Alidina - 2nd primary cancers in pts with sporadic dMMR CRC (@MPishvaian)
    Clinical
    |
    CHEK2 (Checkpoint kinase 2)
    |
    MSI-H/dMMR • CHEK2 mutation
    almost4years
    I received 5 rounds of BEP platinum chemo for germ cell ovarian, mixed immature teratoma and yolk sac in 2013. I have a recently discovered less common Chek2 mutation. Chemo wasn’t working at first and then it did. It was awful. (@Horseri69996114)
    CHEK2 (Checkpoint kinase 2)
    |
    CHEK2 mutation
    almost4years
    Polygenic Risk Score, #FamilyHistory Refine #BreastCancer Risk Assessment in #CHEK2 Mutation Carriers ⁦@MarkRobsonMD⁩ ⁦@sloan_kettering⁩ ⁦@ASCO⁩ #bcsm #CancerResearch #hereditarycancer #ASCO20 #genetics #gcchat Via ⁦@PrecOncNews⁩ https://t.co/Iok2m39Cm2 (@LguzzardiM)
    CHEK2 (Checkpoint kinase 2)
    |
    CHEK2 mutation
    almost4years
    TBCRC048: olaparib in pts with advanced #BreastCancer with germline or somatic mutations in DNA damage response pathway genes ORR: -germline mutations: 33%, gPALB2(82%) -somatic mutations: 31%, BRCA1/2(50%) -No responses observed in ATM,CHEK2 mutations #ASCO20 #BCSM #oncoalert (@jesusanampa)
    Clinical • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • CHEK2 (Checkpoint kinase 2)
    |
    BRCA1 mutation • PALB2 mutation • CHEK2 mutation
    |
    Lynparza (olaparib)
    almost4years
    TBCRC 048 cont: pts got olaparib 300mg bid q3w until PD. 27 germline non BRCA and 26 somatic. 87% had mutations in ATM, CHEK2, PALB2 or sBRCA1/2. Cohort 1: 33% PR, all in PALB2 (9/11). Cohort 2: 31% PR. Nice data, and supports prior Talazoparib results. #ASC020 #bcsm (@GeorgeSledge51)
    Clinical • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PALB2 (Partner and localizer of BRCA2) • BRCA (Breast cancer early onset) • CHEK2 (Checkpoint kinase 2)
    |
    BRCA1 mutation • ATM mutation • PALB2 mutation • CHEK2 mutation
    |
    Lynparza (olaparib) • Talzenna (talazoparib)